| A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression) (NCT05135715) | RemeGen Co., Ltd. | 2022-04-19 |
| A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation (NCT05114603) | Shanghai Henlius Biotech | 2022-03-21 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma (NCT04951583) | Centre hospitalier de l'Université de Montréal (CHUM) | 2021-11-16 |
| Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma (NCT05105100) | University of California, San Francisco | 2021-10-29 |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors (NCT05039801) | M.D. Anderson Cancer Center | 2021-09-30 |
| A Study of GC101 TIL in Advanced Melanoma (10hospital) (NCT05098184) | Shanghai Juncell Therapeutics | 2021-09-26 |
| Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma (NCT04796194) | Lytix Biopharma AS | 2021-06-01 |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies (NCT04902040) | M.D. Anderson Cancer Center | 2021-04-14 |
| CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma (NCT04698187) | Regeneron Pharmaceuticals | 2021-03-11 |
| CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma (NCT04695977) | Regeneron Pharmaceuticals | 2021-02-24 |
| Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial (NCT04462406) | ECOG-ACRIN Cancer Research Group | 2021-02-09 |
| Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma (NCT04871334) | Shandong TheraWisdom Biopharma Co., Ltd. | 2021-02-07 |
| Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut (NCT05274438) | Peking University Cancer Hospital & Institute | 2021-01-26 |
| Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma (NCT04493203) | Yana Najjar | 2020-12-18 |
| Multicenter Study of Safety and Efficacy of Prolgolimab in Patients With Advanced Melanoma in Routine Clinical Practice (NCT05120024) | MelanomaPRO, Russia | 2020-10-14 |
| Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma (NCT04165967) | University Hospital, Basel, Switzerland | 2020-09-17 |
| A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) (NCT04495257) | Yale University | 2020-09-14 |
| A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma (NCT04640545) | Nanjing Leads Biolabs Co.,Ltd | 2020-05-12 |
| Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study (NCT03707574) | National Cancer Institute (NCI) | 2019-07-16 |
| Nab-PCE vs PC for MM After Failure of Anti-PD-1 (NCT03917069) | Peking University Cancer Hospital & Institute | 2019-03-23 |
| Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII (NCT03818893) | Osaka University | 2019-03-01 |
| Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004) (NCT03776136) | Merck Sharp & Dohme LLC | 2019-01-30 |
| Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression (NCT03724968) | Elizabeth Davis | 2019-01-17 |
| Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German Database (NCT05426239) | Bristol-Myers Squibb | 2019-01-09 |
| Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) (NCT03407170) | Merck Sharp & Dohme LLC | 2018-06-28 |
| Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma (NCT03501368) | H. Lee Moffitt Cancer Center and Research Institute | 2018-06-27 |
| APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma (NCT03502330) | Yale University | 2018-06-09 |
| Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma (NCT02965716) | National Cancer Institute (NCI) | 2018-06-05 |
| A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma (NCT03311308) | Yana Najjar | 2018-02-07 |
| A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma (NCT03422445) | Peking University Cancer Hospital & Institute | 2018-01-08 |
| Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma (NCT03200847) | University of Colorado, Denver | 2017-10-31 |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 (NCT02650986) | Roswell Park Cancer Institute | 2017-07-14 |
| Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma (NCT03086174) | Shanghai Junshi Bioscience Co., Ltd. | 2017-03-31 |
| Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer (NCT02981303) | HiberCell, Inc. | 2017-02-22 |
| A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma (NCT02738489) | Jiangsu HengRui Medicine Co., Ltd. | 2016-04-13 |
| A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM) (NCT02663258) | Royal Marsden NHS Foundation Trust | 2016-01-01 |
| Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan (NCT02402699) | Bristol-Myers Squibb | 2015-12-15 |
| YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey (NCT02224768) | Bristol-Myers Squibb | 2015-07-01 |
| A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma (NCT02177110) | Cancer Trials Ireland | 2014-09-01 |
| PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (NCT01621490) | Bristol-Myers Squibb | 2012-09-27 |
| Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma (NCT01614301) | University of Regensburg | 2012-05-01 |
| An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors (NCT01618136) | Eisai Limited | 2012-01-01 |
| Phase II FANG™ in Advanced Melanoma (NCT01453361) | Gradalis, Inc. | 2011-10-01 |
| Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (NCT01134614) | National Cancer Institute (NCI) | 2010-12-28 |
| A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma (NCT01212276) | Morphotek | 2010-12-01 |
| Phase II Study of Tesetaxel in Metastatic Melanoma (NCT01064713) | M.D. Anderson Cancer Center | 2010-02-01 |
| Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma (NCT00920907) | Bristol-Myers Squibb | 2009-08-01 |
| Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine (NCT00796991) | Bristol-Myers Squibb | 2009-02-01 |
| Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma (NCT00813449) | Simcere Pharmaceutical Co., Ltd | 2008-08-01 |
| Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma. (NCT00688090) | Mannkind Corporation | 2008-06-01 |
| A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine (NCT00542893) | Genta Incorporated | 2006-04-01 |
| Study of Temzolomide and Gleevec in Advanced Melanoma (NCT00667953) | Abramson Cancer Center at Penn Medicine | 2003-01-01 |